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ABSTRACT
Trypanosoma brucei survives in mammals through
antigenic variation, which is driven by RAD51-
directed homologous recombination of Variant
Surface Glycoproteins (VSG) genes, most of which
reside in a subtelomeric repository of >1000 silent
genes. A key regulator of RAD51 is BRCA2, which in
T. brucei contains a dramatic expansion of a motif
that mediates interaction with RAD51, termed the
BRC repeats. BRCA2 mutants were made in both
tsetse fly-derived and mammal-derived T. brucei,
and we show that BRCA2 loss has less impact on
the health of the former. In addition, we find that
genome instability, a hallmark of BRCA2 loss in
other organisms, is only seen in mammal-derived
T. brucei. By generating cells expressing BRCA2
variants with altered BRC repeat numbers, we
show that the BRC repeat expansion is crucial for
RAD51 subnuclear dynamics after DNA damage.
Finally, we document surprisingly limited co-
localization of BRCA2 and RAD51 in the T. brucei
nucleus, and we show that BRCA2 mutants display
aberrant cell division, revealing a function distinct
from BRC-mediated RAD51 interaction. We
propose that BRCA2 acts to maintain the huge
VSG repository of T. brucei, and this function has
necessitated the evolution of extensive RAD51
interaction via the BRC repeats, allowing
re-localization of the recombinase to general
genome damage when needed.
INTRODUCTION
African trypanosomes, such as Trypanosoma brucei, are
protistan parasites that infect mammals in sub-Saharan
Africa, where they are responsible for devastating
disease in both humans and their domestic animals.
Survival of T. brucei in mammals is dependent on anti-
genic variation, which involves switches in expression of
variant surface glycoproteins (VSGs) that form a protect-
ive ‘coat’ on the parasite cell surface (1,2). One VSG is
expressed at a time, and continual switching to immuno-
logically distinct VSGs allows part of the infecting popu-
lation to survive successive waves of eradication by host
immunity, prolonging the infection and enhancing
transmission.
VSG switching involves the activation of silent VSG
genes by recombination, which results in copying the
silent genes into specialized sites of transcription, termed
VSG expression sites (3). VSGs are copied from an
enormous (>1000 distinct genes) silent repository,
mainly composed of subtelomeric VSG arrays. Most
recombination-based VSG switching occurs through
gene conversion reactions (2), which can take two forms:
activation of functionally intact VSGs (5% of the reposi-
tory) by whole gene conversion or activation of VSG
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pseudogenes (85% of the repository) by segmental gene
conversion (2,4). Intact VSG gene conversion involves
homologous recombination (HR), a universally conserved
process that is critical in all organisms for reversing
genotoxic damage and ensuring the completion of DNA
replication (5). The key enzyme of eukaryotic HR is
Rad51, which forms nucleoprotein ﬁlaments on single-
stranded (ss) DNA at sites of damage and catalyses the
transfer of the broken molecule to homologous sequences
in an unbroken DNA molecule, leading to repair.
Mutation of RAD51 in T. brucei impairs switching of
intact VSGs (6), but the contribution of RAD51 and
HR to segmental VSG conversion is unclear. Rad51 HR
reactions are mediated by a number of proteins, which
either directly inﬂuence Rad51 activity or act in
upstream or downstream HR reaction steps (5).
Trypanosoma brucei HR factors that perform both roles,
such as RAD51 paralogues (7,8) and RMI1/TOPO3
(9,10), have been shown to act in VSG switching,
reinforcing a close association between general HR and
antigenic variation.
BRCA2 has emerged as a key mediator of Rad51
function and is widely conserved, although not ubiqui-
tous, in eukaryotes (11). BRCA2 orthologues vary consid-
erably in size, from >3000 amino acids in mammals to
proteins only 30 and 10% that size in Ustilago maydis
(Brh2) (12) and Caenorhabditis elegans (CeBRC-2) (13),
respectively. BRCA2 sequence conservation is limited
out with two domains, termed the BRC repeats and the
DSS1-DNA binding domain (DBD). BRC repeats
mediate interaction with Rad51 during HR (14) and are
a key conserved functional element, as each BRCA2
orthologue seems to retain at least one (11). In vertebrates,
BRCA2 also binds Rad51 via an unrelated C-terminal
sequence; binding here is regulated by cell cycle-dependent
phosphorylation (15) and is speciﬁc for Rad51–DNA ﬁla-
ments (16,17). Non-BRC repeat binding of Rad51 may be
a conserved feature of BRCA2, as it is also seen in
U. maydis (18) and C. elegans (13), but whether it
provides a functional link to cell cycle progression is
unclear. Indeed, the detailed role of BRCA2 in promoting
HR is still being unravelled. Initial models suggested that
the BRC repeats of vertebrate BRCA2 bind Rad51 as
monomers and counter RAD51 nucleoprotein ﬁlament
formation on ssDNA. Dephosphorylation of the
C-terminal Rad51 binding site then allows this region to
promote the formation of Rad51 nucleoprotein ﬁlaments,
which are disassembled via the BRC repeats to terminate
HR when the C-terminus is rephosphorylated as the cells
proceed to mitosis (19). However, other work has shown
that the BRC repeats of mammalian BRCA2 inhibit
Rad51 binding to double-stranded (ds) DNA, promote
binding to ssDNA and can support strand exchange in
the absence of the C-terminal Rad51 binding site
(20–23). Indeed, yet further studies have suggested that
vertebrate BRCA2–Rad51 interaction via BRCA2’s
C-terminus acts in an HR-independent role to stabilize
DNA replication forks whose progression has stalled
(24–26). Such issues have been little addressed in other
eukaryotes.
Trypanosoma brucei and related kinetoplastid parasites
encode BRCA2 orthologues, in which strong homology is
seen in the C-terminus around the DBD, but with little
obvious sequence conservation with human BRCA2 in the
C-terminal Rad51 binding region (Supplementary Figures
S1–S3). Upstream of the DBD, kinetoplastid BRCA2
proteins are signiﬁcantly shorter than human BRCA2,
and here, sequence homology seems to be limited to the
BRC repeats (Supplementary Figure S1). However, the
number of BRC repeats in T. brucei BRCA2 is highly
unusual (Figure 1) (27): up to 15 repeats have been
described, nearly double the number found in mammalian
BRCA2 (eight BRC repeats) (11), and far greater than in
BRCA2 of Arabidopsis thaliana (four BRC motifs) (28) or
in C. elegans (13) and U. maydis (12), each of which has
only a single BRC repeat. The BRC repeat number in
T. brucei BRCA2 seems to be a recent evolutionary ex-
pansion, as BRCA2 proteins from Trypanosoma cruzi and
Leishmania major, related intracellular kinetoplastid para-
sites, have two non-identical BRC repeats (Supplementary
Figure S1). The arrangement of the BRC repeats in
T. brucei BRCA2 is also unusual: most of the repeats
are identical in sequence and all form a tandem array
(27). This contrasts with BRCA2 in humans
(Supplementary Figure S1), plants (11) and at least some
Drosophila species (29), where the BRC repeats are
variable in sequence and dispersed throughout the
polypeptide.
Little work has examined why BRCA2 in some organ-
isms have evolved multiple BRC repeats, whereas in
others a single BRC repeat is sufﬁcient for function. In
mammals, the BRC repeats fall into two categories (21):
isolated BRC repeats in one category display relatively
high afﬁnity Rad51 binding, reduce the adenosine
triphosphatase activity of the recombinase and stimulate
strand exchange in vitro; in contrast, BRC repeats in the
second category have low afﬁnity for Rad51 and do not
affect the recombinase’s adenosine triphosphatase or
strand exchange activities. Thus, it is modelled that
BRCA2’s role in Rad51 HR is through a two-step
process, directed by the differing BRC–Rad51 inter-
actions, aiding the formation of Rad51 nucleoprotein ﬁla-
ments on ssDNA (21). How this occurs in the context of
the complete protein and during in vivo repair remains to
be examined. In T. brucei, we tested previously whether
the BRC repeat expansion is an adaptation for HR during
VSG switching. To our surprise, mammal-derived blood-
stream form (BSF) cells modiﬁed to express BRCA2
variants with only a single BRC repeat, whereas
impaired in general HR and in re-localization of RAD51
to subnuclear foci after damage, were competent for
switching of intact VSGs (27). Here, we more comprehen-
sively dissect the need for a BRC repeat array and show
that BRC repeat number is a critical determinant of
RAD51 subnuclear dynamics. We also analyse BRCA2
and RAD51 localization in T. brucei and show that,
contrary to other eukaryotes, these factors rarely co-local-
ize in subnuclear repair foci. In addition, we show that
chromosome instability, described previously in BSF
T. brucei BRCA2 mutants, is not seen in procyclic form
(tsetse midgut-derived; PCF) parasites, where the
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phenotypes of BRCA2 loss are less severe. Finally, we
document replication-associated functions of BRCA2
that localize to the C-terminus of the protein. We
propose that these data are explained by BRCA2 acting
in VSG array stability in a speciﬁc process linked to anti-
genic variation, which has necessitated the evolution of
extensive RAD51 interaction, via expanded BRC
repeats, to allow redistribution of RAD51 to general
damage when needed.
MATERIALS AND METHODS
Trypanosoma brucei strains, growth and mutation of
BRCA2 and RAD51
Trypanosoma brucei BSF cells (strain Lister427 MITat1.2)
were grown at 37C in HMI-9 medium. PCF cells (strain
TREU927 or Lister427) were grown in SDM-79 medium
at 27C. BSF BRCA2mutants were generated as described
previously (27); PCF mutants used the same constructs
and were selected with 5 mgml1 blasticidin and
0.5 mgml1 puromycin. Cell growth was analysed in vitro
by diluting the BSF cells to 5 104ml1 and measuring
cell density (using a haemocytometer, Bright-line, Sigma)
at 24 h time intervals; PCF cells were diluted to
5 105ml1, and cell density was measured using a Z2
Coulter particle count and size analyser (Beckman). To
generate RAD51 mutants, sequences derived from the
start and end of the RAD51 ORF, covering equivalent
coding sequence to that contained in previous RAD51 dis-
ruption constructs (6), were generated by high-ﬁdelity
polymerase chain reaction (PCR)-ampliﬁcation and
cloned into pBluescript. The same blasticidin-resistance
cassette used for BRCA2 deletion was then cloned
between the RAD51 sequences, generating
RAD51::BSD. This was transformed into RAD51+/
cells, in which one RAD51 allele had been disrupted by
puromycin resistance insertion (6), transformants were
selected with 2.5mgml1 blasticidin and 0.5 mgml1
puromycin.
Generation of BRCA2 variants
ORFs encoding full-length BRCA2 and the BRCA2
variants were cloned, after high-ﬁdelity PCR-
ampliﬁcation, into EcoRV-digested pRM482, which
Figure 1. Growth and repair efﬁciency of T. brucei BRCA2 mutants. (A) Locations of conserved domains are shown diagrammatically within the
T. brucei BRCA2 polypeptide: BRC repeats (black boxes), and sub-domains of the DSS1-DNA binding region (grey boxes: H, helical domain;
T, tower domain; 1, 2, 3, OB domains). (B) Growth is shown of WT, BRCA2 heterozygous (+/) and brca2 homozygous (/) mutants cells in
T. brucei Lister427 bloodstream form (427BSF) cells and in PCF cells from Lister427 (427PCF) and TREU927 (927PCF) strains. Cell densities were
measured in vitro at 24 h intervals; bars indicate standard errors from three experiments. (C) EC50 values of the same T. brucei BSF and PCF strains
are shown, comparing WT, BRCA2+/ and brca2/ cells exposed to phleomycin. EC50 values are the mean from three experimental repetitions
expressed as a percentage of WT; bars indicate standard error.
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targets genes to the tubulin array and is identical to
pRM481 (8), except that the phleomycin resistance ORF
is replaced with G418 resistance (neomycin phospho-
transferase). Full-length T. brucei BRCA2 was
PCR-ampliﬁed with Tbfor (50-CCCGATATCATGAGC
CACAAAAAAGGAAGACAA; EcoRV site underlined)
and Tbrev (50-CCCGATATCCTATTCTCGCATAAGA
TCAGCGAC). Trypanosoma vivax BRCA2: Tvivfor2
(50-CCCCGATATCATGAAGCAGCGGCAAGTAGG
TGAA) and Tvivrev3 (50-CCCCGATATCCTACACTGA
ACTCTCCTCCTGCAT). The BRCrep coding sequence:
BRCA-TRUNC 50 (50-CCCCTCGCGAATGTACGGGA
CTGAAAATGGCCAAGAG; NruI) and BRCA-
TRUNC 30 (50-CCCCTCGCGACTACGGCTTTCTTG
CTAGCTTGGATG). BRCA2 Cterm coding sequence:
BRCA-NO-BRC (50-CCCTCGCGAATGTCGGGAGC
AGGTGCCTCCTTGTCG) and Tbrev2. The BRC–repli-
cation protein A (RPA) fusion was generated by PCR-
amplifying the T. brucei BRCA2 BRC repeat region and
RPA ORF separately and then cloning them together into
pRM482. The BRCrep coding sequence was ampliﬁed
with BRCA–RPA50 (50-CCCCGATATCATGTACGGG
ACTGAAAATGGCCAAGAG; EcoRV) and BRCA–
RPA30 (50-CGGCTTTCTTGCTAGCTTGGATG); RPA
was ampliﬁed with RPA 50 (50-CAGCAGCCATCACAA
CAACAG) and RPA 30 (CCCCGATATCTTACAAGTA
GGCATTAATGC; EcoRV). Trypanosoma brucei BRCA2
with 1 BRC repeat was generated by PCR-amplifying the
coding sequence immediately upstream of the BRC
repeats and a region encompassing the most C-terminal
coding repeat and all downstream sequence separately,
then cloning the two fragments together into pRM482.
The upstream fragment was PCR-ampliﬁed with Tbfor
and BRCVAR503 (50-CTCTTGGCCATTTTCAGT
CCC); the downstream with BRCVAR305 (50-AGCACT
GCGGTACAAGGAAATTCC) and BRCVAR303
(50-CCCTCGCGACTATTCTCGCATAAGATCAGCG
AC; NruI). Trypanosoma brucei BRCA2 with 4, 7 and 10
BRC repeats were synthesized and PCR-ampliﬁed with
Tbfor and Tbrev. To C-terminally tag BRCA2 with a
12Myc epitope, a 491-bp region of the 30-end of the
ORF was PCR-ampliﬁed with primers 32 (50-CCCAAG
CTTGAAGTGGAAAGTTTGTAGTGTCC; HindIII)
and 33 (50-CCCTCTAGATTCTCGCATAAGATCAGC
G; XbaI) and cloned into the vector pNATX12myc (30);
after digestion with SphI, this was transformed into
BRCA2+/ cells (::PUR) and transformants selected
with 10 mgml1 blasticidin.
Microscopy
The 5 106 BSF cells or 5 105 PCF cells were harvested
by centrifugation at room temperature for 10 min at 735g
and washed once in phosphate buffered saline (PBS). The
cell pellet was resuspended in 50 ml PBS and spread thinly
on a silane prepared slide (Sigma) and allowed to air dry.
Slides were soaked in ice cold methanol for 15 min and
washed in cold PBS twice. Slides were blocked by immer-
sion in cold 5% fetal calf serum (FCS) in PBS for 1 h.
Blocking solution was removed, and the slides were
transferred to a dark chamber before adding rabbit
polyclonal anti-TbRAD51 antibody diluted 1:1000 in
2% of FCS/PBS for 1 h. The slides were washed twice in
PBS for 5 min and then returned to the humid chamber.
Alexa Fluor conjugated secondary antibodies were added,
diluted in 2% of FCS/PBS and incubated for 1 h: Alexa
594-conjugated goat-derived anti-rabbit IgG (1:7000
dilution) was used to detect RAD51, and Alexa 488-
conjugated mouse-derived anti-myc IgG (1:7000
dilution) was used to detect BRCA2myc. Finally, the
slides were washed twice in PBS for 5min, allowed to
air dry, then mounted in Vectashield with DAPI
(4,6-diamidino-2-phenylindole) (Vector Laboratories).
Fluorescence microscopic analysis was performed using
a Deltavision confocal microscope, and ﬂattened projec-
tions of the resulting image slices were obtained using
softWoRx explorer (Applied Precision).
Assaying DNA damage sensitivity
Sensitivity of the cell lines to methyl methanesulphonate
(MMS) and phleomycin was assessed by the metabolic
reduction of Alamar blue (31). Here, cells in mid-
logarithmic growth were plated at a density of 2 105
cellsml1 for BSF cells and 5 105 cellsml1 for PCF
cells in a 96-well dish (200 ml/well) in medium containing
doubling dilution concentrations of drug. After 48 h
growth, 20 ml of Alamar blue (from a 0.125mgml1
stock of resazurin, Sigma) was added to each well, and
the plates were incubated in the dark for 24 h, when the
ﬂuorescence in each well was determined ﬂuorometrically
(PerkinElmer LS55) at 530 nm excitation wavelength and
590 nm emission wavelength.
Pulsed-ﬁeld gel electrophoresis
Pulsed-ﬁeld gel electrophoresis (PFGE) was carried out
essentially as described in (27). In brief, agarose plugs
containing genomic DNA from 1 108 cells were
prepared and separations of megabase-chromosomes con-
ducted using 1.2% of agarose (Seakem LE) in a
CHEF-DR III apparatus (BioRad). Gels were
electrophoresed in 2 l of electrophoresis buffer (1 TB1/
10E: 90mM of Tris, 90mM of boric acid, 2mM of
ethylenediaminetetraacetic acid). Before electrophoresis,
the agarose genomic DNA plugs were prepared by three
rounds of dialysis in electrophoresis buffer. Gels were
electrophoresed at 15C with an included angle of 120
and 2.5V cm1 for 144 h with an initial switch time of
1400 s and ﬁnal switch time of 700 s.
Aqueous fractionation
Aqueous fractionation was performed essentially as
described in (32). The 5 108 PCF cells were centrifuged
at 1620g and washed twice in 5ml ice cold fractionation
buffer A [FBA; 150mM of sucrose, 20mM of KCl, 3mM
of MgCl2, 20mM of HEPES–KOH (pH 7.9), 1mM of
DTT and 1 complete ethylenediaminetetraacetic acid-
free protease inhibitor cocktail (Roche)]. Cells were
re-suspended in 1ml of FBA with 0.2% Nonidet P-40.
The cell suspension was passed through a 26-gauge
syringe needle three times. The suspension was centrifuged
at 20 000g for 10 min at 4C. The supernatant was
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separated and centrifuged again at 20 000g at 4C; this
supernatant contains the soluble cytoplasmic proteins.
The cell pellet was re-suspended in 500 ml of FBA and
passed through a 26-guage syringe needle 15 times. The
suspension was centrifuged at 20 000g at 4C for 10 min.
The supernatant was removed and the pellet re-suspended
in 500 ml of FBA; this suspension contains the soluble
nuclear proteins. The proteins were separated by sodium
dodecyl sulphate–polyacrylamide gel electrophoresis
(SDS–PAGE) on NuPAGE Novex Bis–Tris 10% mini
gels (Invitrogen), western blots prepared using a Mini
Trans-Blot Cell (Bio-Rad) and Hybond ECL nitrocellu-
lose (Amersham) and the blots probed with anti-RAD51
(1:500 dilution), anti-OPB1 (1:1000) and anti-NOG1
(1:5000) antiserum. Bound antiserum was detected by
horseradish peroxidase conjugated secondary antiserum
and the SuperSignal West Pico Chemiluminescent
Substrate (Pierce).
RESULTS
BRCA2 mutation causes more pronounced phenotypes
in bloodstream form than in procyclic form T. brucei
To examine the functions of BRCA2 in T. brucei, we used
reverse genetics to delete the entire BRCA2 ORF in BSF
and PCF T. brucei cells of strain Lister427, as well as in
PCF TREU927 cells where 800 VSGs have been pos-
itionally annotated (4). In each case, two independent
mutants were derived by two rounds of transformation,
generating ﬁrst BRCA2 heterozygous (+/) mutants and
then homozygous (/) null mutants (Figure 1); the mu-
tations were conﬁrmed by Southern analysis
(Supplementary Figure S4). Comparing the growth of
the / mutants with wild-type (WT) cells and+/ pre-
decessors showed that the impact of BRCA2 loss was not
equivalent in the two life cycle stages (Figure 1B). In BSF
cells, the brca2/ mutants, although viable, showed sig-
niﬁcantly impaired growth, with population doubling
times (pdts; 16 h) nearly 2-fold increased relative to
WT and +/ cells (8.5 h). In contrast, PCF brca2/
mutants displayed a more modest increase in pdts (15.5
and 13 h for TREU927 and Lister427/ cells, respect-
ively, relative to 11 h for WT and +/ cells). In each
case, re-expression of BRCA2 (//+ cells, see below)
in the brca2/ cells restored growth to WT rates,
demonstrating that this phenotype is a direct consequence
of BRCA2 loss rather than secondary effects.
To examine the contribution of BRCA2 to T. brucei
DNA repair, the sensitivity of the mutants to induced
DNA damage was examined by comparing growth in
the presence of either phleomycin (BLE; Figure 1C), a
glycopeptide antibiotic that generates ssDNA and
dsDNA breaks (33) or MMS (Supplementary Figure
S5), an SN2 alkylating agent. To quantify this, the EC50
(concentration that resulted in death of 50% of cells) of
the WT,+/ and / cell lines in each life cycle stage and
in each strain was determined by measuring the metabolic
capacity of the cells using Alamar blue as an indicator
(31). Here again, the effect of BRCA2 loss was more
marked in BSF than in PCF cells. Lister427 BSF
brca2/ mutants were 5–10-fold more sensitive to BLE
than WT cells, whereas PCF brca2/ cells displayed at
most 2-fold greater sensitivity. BSF brca2/ mutants
displayed less pronounced increased sensitivity to MMS
(3 fold), but this was again greater than seen for the PCF
homozygous mutants of either strain. Indeed, the
brca2/ mutants in Lister 427 PCF cells showed only
a limited increase in MMS sensitivity relative to WT
(Supplementary Figure S5).
Trypanosoma brucei BRCA2 BRC repeat number is an
important determinant of RAD51 subnuclear
redistribution after DNA damage
To ask why T. brucei BRCA2 requires an expanded array
of BRC repeats, we expressed a number of BRCA2
variants in the brca2/ cell lines (Figure 2). In each
case, the variants were expressed by integration of the
ORFs into the tubulin array, the same strategy used pre-
viously to express BRCA2 variants with a single BRC
repeat (27) (see later in the text). Here, we constructed
and expressed BRCA2 variants with increasing BRC
repeat number (Figure 2A). We refer to these as 1BRC,
4BRC, 7BRC and 10BRC; 1BRC retains only the
C-terminal, sequence degenerate BRC repeat, whereas
the others have additionally 3, 6 or 9 upstream conserved
BRC repeats, respectively. Integration of each BRCA2
variant, as well as the larger full-length BRCA2 allele
from the Lister427 genome (12 BRC repeats), was
analysed by Southern analysis (Supplementary Figure
S6) and conﬁrmed for all except 7BRC in Lister427 PCF
cells, where two BRCA2 gene copies were apparent.
Expression of mRNA for each variant was analysed by
quantitative reverse transcriptase-PCR (as we could not
detect BRCA2 protein with an anti-peptide antiserum):
BRCA2 mRNA was present in each variant expresser at
50% of the quantity seen in WT cells, consistent with
single gene integrations; the exception to this was 7BRC in
PCF Lister 427, which showed approximate WT levels of
mRNA (data not shown).
We ﬁrst considered the possibility that the increased
BRC repeat number may be because BRCA2 acts as a
carrier for transit of RAD51 into the nucleus, as has
been described in human cells (34) and Leishmania (35).
If so, greater BRC numbers may reﬂect the need for
abundant nuclear RAD51 in T. brucei. To test this,
aqueous fractionation was carried out on T. brucei
whole cell extracts (32) from PCF WT TREU927 and
BRCA2 mutant cells, and from the BRC variant ex-
pressers. In all cases, nuclear and cytoplasmic extracts
were examined before and after BLE treatment (1 mgml1
for 18 h) by probing western blots of the separated
proteins sequentially with anti-RAD51, anti-OPB1 (cyto-
plasmic) (36) and anti-NOG1 (nuclear) (37) antiserum
(Figure 2B). In all the cells, including the brca2/
mutants, RAD51 was detected in both the nuclear and
the cytoplasmic fractions before and after
BLE-induction of DNA damage. There was also no
evidence that the number of BRC repeats affected the
relative amount of RAD51 in the nucleus and cytoplasm.
We conclude that BRCA2 is not a critical nuclear
Nucleic Acids Research, 2013, Vol. 41, No. 2 947
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transport factor for RAD51 in T. brucei, despite the
absence of detectable nuclear localization signals in the
polypeptide sequence of the recombinase (data not
shown).
Relocalization of HR factors, including Rad51, to
microscopically detectable foci after DNA damage is a
conserved response in eukaryotes and bacteria, and such
foci represent the concentration of factors into putative
repair centres (38,39). The brca2/ mutants in BSF
Lister427 T. brucei display a marked deﬁciency in their
ability to form RAD51 foci after DNA damage (27). To
date, RAD51 foci have not been described in PCF cells.
PCF TREU927 BRCA2 mutant cells were, therefore,
treated with BLE (1 mgml1 for 18 h) and RAD51
visualized with anti-RAD51 antiserum by immunoﬂuores-
cence. In the absence of DNA damage, nuclear RAD51
foci were seen in only 2% of cells (data not shown),
whereas 75% of WT and BRCA2+/ cells had detect-
able foci (1 to >4 foci/nucleus) after BLE treatment
(Supplementary Figure S7A), a quantitatively similar
response to that of BSF T. brucei (7,8). The brca2/
cells seemed to have lost the ability to form RAD51 foci
(Figure 2C and Supplementary Figure S7), suggesting a
key role for BRCA2 in this process, as seen in BSF cells.
The ability of BRCA2 BRC variants to support RAD51
foci formation was next examined in both the BSF and
PCF cells in the same way (Figure 2C; examples of foci in
Supplementary Figure S8). In the absence of DNA
Figure 2. The BRC repeat number of T. brucei BRCA2 affects the efﬁciency of RAD51 subnuclear foci formation. (A) A diagrammatic illustration
of the strategy for expression of BRCA2 variants with differing numbers of BRC repeats. BRCA2 variant ORFs were targeted to the tubulin array
for expression in brca2/ cells, using ﬂanking b-a and a-b tubulin intergenic regions (IR) for homologous integration. Transformants were selected
by G418 resistance using a neomycin phosphotransferase ORF (NEO), which was upstream of the BRCA2 variant ORF; actin IR sequence between
the NEO and BRCA2 ORFs was for mRNA processing. The BRCA2 variants differed only in the number of BRC repeats they encode (black bars):
1, 4, 7, 10 or 12, indicated by 1BRC, 4BRC, 7BRC, 10BRC or BRCA2, respectively. Other conserved domains are indicated: DBD and two putative
NLS. (B) Aqueous fractionation was performed to generate protein fractions enriched in soluble cytoplasmic (C) and nuclear proteins (N) from WT
TREU927, BRCA2+/, brca2/ and BRCA2 BRC variant expresser cells; ‘hyphen’ indicates fractions prepared without phleomycin (BLE)
treatment, and ‘plus’ indicates fractions prepared after phleomycin treatment (1 mg ml1 for 18 h). Fractions were separated by SDS–PAGE and
western blotted before being sequentially probed with anti-RAD51, anti-OPB1 and anti-NOG1 antiserum; protein sizes are indicated (kDa). (C) For
PCF TREU927 and BSF Lister427 T. brucei, WT, brca2/ mutants and BRC variant expressers were treated with 1mg ml1 phleomycin for 18 h,
and the number of cells with a speciﬁc number of subnuclear RAD51 foci (0, 1, 2, 3, 4, >4) counted; graphs represent the numbers of foci-containing
cells as a percentage of the total number of cells counted (N).
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damage, RAD51 foci were again rarely seen, irrespective
of the BRC repeat number (data not shown). However,
after BLE treatment, the number of cells with detectable
RAD51 foci increased linearly as the BRC repeat number
increased. As described previously (27), BSF cells express-
ing the 1BRC variant were markedly impaired in the for-
mation of RAD51 foci, which were seen in <10% of these
cells. As the number of BRC repeats in the expressed
BRCA2 variants increased, the number of cells in the
population that displayed RAD51 foci increased, as did
the number of foci seen in individual cells. The same trend
was also seen in PCF cells, although in this life cycle stage,
each BRC variant seemed better at supporting the forma-
tion of RAD51 foci than the same variant in BSF cells
(e.g. 45% of cells had detectable foci when expressing
1BRC). To ensure that these ﬁndings are not because of
differences in the levels of RAD51 in the BRC variants,
western analysis was performed in all cells before and after
BLE treatment (Supplementary Figure S9). RAD51 levels
seemed equivalent in all the BRC variants (and in the
brca2/ cells) in both life cycle stages, and in none of
the cells did we detect an increase in RAD51 expression
after BLE-induced DNA damage. These data indicate that
the BRC repeat number of T. brucei BRCA2 is a key de-
terminant of the efﬁciency with which RAD51 is
relocalized to foci after BLE damage. Moreover, they
may suggest that the need for an expanded array of
BRC repeats in BRCA2 is more pronounced in BSF
cells, as each BRC repeat variant was less effective at
moving RAD51 to BLE damage in these cells relative to
PCF cells.
Given the above relationship between RAD51 foci for-
mation efﬁciency and BRCA2 BRC repeat number, we
next asked whether the efﬁciency of DNA damage repair
is also dependent on BRC number. Growth curves showed
that the increased pdts of the brca2/ cells were reverted
to WT rates by expression of any BRC variant
(Supplementary Figure S10), even in the BSF cells that
show a more pronounced growth impediment. Next, we
measured the EC50 values of the BSF and PCF BRC
variant expressers in BLE and MMS and compared
these with WT and brca2/ mutants (Figure 3 and
Supplementary Figure S10). BSF cells expressing the
1BRC variant displayed signiﬁcantly decreased survival
in both BLE and MMS relative to WT cells, suggesting
repair deﬁciency, although their EC50 values were slightly
higher than the brca2/ cells, suggesting some ability to
complement the mutation. Nonetheless, this is consistent
with the ﬁnding that this variant, in this life cycle stage, is
largely deﬁcient in RAD51 foci formation (Figure 2C) and
HR (27). In contrast, in PCF cells of either strain, there
was no evidence for such repair deﬁciency of the 1BRC
variant, which showed EC50 values of at least that of the
WT cells. Expression of BRCA2 with 4, 7 or 10 BRC
repeats, in either BSF or PCF cells, restored survival of
the brca2/ mutants to at least WT levels, with each
BRC variant displayed EC50 values essentially indistin-
guishable from the cells expressing full-length BRCA2.
Thus, although reducing the number of BRC repeats in
T. brucei BRCA2 affects the capacity of the protein to
mediate relocalization of RAD51 to foci after BLE
treatment, this is not reﬂected in the ability of such
variants to support the repair of BLE-induced damage.
Indeed, only when the BRC number is reduced to a
single unit of the repeat array, is an effect seen on repair
efﬁciency, and even then only in parasites that reside in the
mammal.
Trypanosoma brucei genome instability in BRCA2
mutants is detectable only in mammalian stage parasites
After prolonged growth (290 generations), brca2/
mutants in BSF Lister427 T. brucei display genomic in-
stability, detectable by visible reductions in the size of
many megabase-chromosomes, at least some of which
arises because of VSG loss (27). Southern analysis of
clones of BSF Lister427 brca2/ mutants after only
150 generations revealed loss of one or more copies of
the multicopy VSG121 gene (Figure 4A) to the same
extent as seen after 2-fold longer growth (27), suggesting
instability arises more quickly than previously thought. To
date, the VSG repertoire in the T. brucei genome has been
positionally annotated only in strain TREU927 (4). To
allow a ﬁner examination of the loss of VSGs and
genome instability after BRCA2 mutation, PCF
TREU927 brca2/ mutants, as well as WT and +/
mutants, were grown for 380 generations, cloned and
the genome analysed. Our assumption was that the in-
stability observed previously reﬂects a general role for
BRCA2 in genome maintenance during growth. To our
surprise, on using PFGE (Supplementary Figure S11A),
we found little evidence for the extensive changes in size of
the megabase-chromosomes in the brca2/ mutants seen
previously in BSF cells (27). Southern blots were per-
formed on the clones (Figure 4C), probing with four
annotated VSGs (gene IDs: Tb09.244.0140,
Tb08.27P2.610, Tb0827P2.530 and Tb09.244.1310). Each
of these genes belong to subtelomeric array VSG
‘families’, within which we could predict at least four
VSGs that showed 56–100% sequence identity. For each
VSG, there was no evidence for either gene loss or re-
arrangements that led to changes in restriction digest
patterns. Thus, even after more extensive growth,
brca2/ mutants in PCF TREU927 cells do not
display equivalent levels of genome instability to that
seen in BSF Lister427 brca2/ mutants.
A potential explanation for the aforementioned dichot-
omy between BSF and PCF T. brucei could be differences
in the relative size or composition of the VSG repertoire in
the TREU927 and Lister427 strains. The genome size of
TREU927 is among the smallest of the T. brucei strains
examined (40), and microarray data suggest that the larger
size of the Lister427 genome, as well as chromosome size
polymorphisms between the strains, is accounted for by
greater numbers of VSGs in the subtelomeres of the
megabase-chromosomes (41). Assuming that the main
cause of instability in brca2/ cells is VSG-associated
rearrangements, then the putatively smaller VSG reper-
toire of TREU927 may mean that rearrangements are
less frequent or less detectable. Alternatively, the VSG
composition of strain Lister427 may contribute to instabil-
ity: if greater numbers of high sequence identity families of
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Figure 4. Genome instability after BRCA2 mutation is seen only in bloodstream form T. brucei. Southern blots are shown of genomic DNA from
Lister427 BSF (A), Lister427 PCF (B) and TREU927 PCF (C) T. brucei, comparing WT, BRCA2+/ and brca2/ clones that had been grown
in vitro for 150, 380 and 230 generations, respectively. Lister427 genomic DNA was digested with XmnI, and each blot was probed with
VSG121, which is found as a telomeric (Tel) and four putative subtelomeric copies; lanes with clones in which at least one VSG121 copy has been
lost are indicated by asterisk. DNA from TREU927 PCF cells was digested with HindIII, and the blots probed with DNA fragments recognizing one
of four distinct VSG families, designated VSG1, VSG2, VSG3 or VSG4. Size markers (kb) are indicated.
Figure 3. Repair efﬁciency of T. brucei cells expressing BRCA2 variants with altered BRC repeat number. EC50 values after exposure to phleomycin
are shown of WT cells, brca2/ mutants and brca2/ mutants expressing either BRCA2 variants with altered numbers of BRC repeats (1BRC,
4BRC, 7BRC and 10BRC) or full-length BRCA2 (see Figure 2 for details); values are the mean from three experiments expressed as a percentage of
WT, and vertical lines indicate standard error. This analysis was conducted T. brucei Lister427 bloodstream form (427BSF) cells, and in procyclic
form cells from Lister427 (427PCF) and TREU927 (927PCF) strains.
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VSGs exist in Lister427 relative to TREU927, then they
may be more prone to HR reactions. To test these
possibilities, genome stability was examined in clones of
PCF Lister427 brca2/ mutants grown in culture for
230 generations. Southern analysis of VSG121 showed
none of the characteristic loss of copies seen in the BSF
mutants (Figure 4B) (27). PFGE (Supplementary Figure
S11B) conﬁrmed this greater stability across the PCF
genome: a predominant uniformity in the size of each
chromosome in the mutant clones was observed, with
only one exception (visible reduction in size of a single
chromosome of 2.3Mb in one clone). Taken together,
the above data suggest, remarkably, that genome instabil-
ity after loss of BRCA2 in T. brucei, rather than being
common to PCF and BSF cells, is either a BSF-speciﬁc
process or is more prevalent in that life cycle stage.
Trypanosoma brucei BRCA2 and RAD51 display only
partial subnuclear co-localization, even after induced
DNA damage
Although T. brucei BRCA2 inﬂuences the formation or
maintenance of RAD51 nuclear foci after damage, it is
not clear whether the two proteins (as well as other
repair factors) interact in these putative repair structures
in the parasite, as has been described in other eukaryotes
(42–44). We, therefore, performed co-immunoﬂuoresence
microscopy to localize BRCA2 and RAD51. To do this,
we transformed PCF TREU927 BRCA2+/ cells with a
construct that modiﬁes the remaining BRCA2 ORF, such
that it expresses C-terminally myc-tagged BRCA2
(BRCA2myc). Southern blotting conﬁrmed that the only
BRCA2 allele in this strain was myc-tagged, and assaying
MMS sensitivity showed that such epitope addition did
not impede BRCA2 function (Supplementary Figure
S12). The proteins were then visualized (BRCA2 with
anti-myc antibody, and RAD51 with polyclonal
anti-RAD51 antiserum) in cells grown in the absence of
induced DNA damage, and after 5 (Figure 5) or 24 h (data
not shown) growth in BLE. Unlike RAD51, for which no
signal is seen by co-immunoﬂuoresence in the absence of
induced damage, BRCA2myc was readily detected in the
nucleus before BLE treatment. In most cells (67%),
BRCA2myc was found in multiple foci-like punctate
structures (Images 1 and 2, Figure 5), positioned either
around the nuclear periphery or throughout the nucleus.
In other cells, BRCA2myc localization was less focal,
either because staining was visible throughout the
nucleus or because no clear subcellular staining was
apparent (27%), or because BRCA2myc was seen in per-
ipheral nuclear ‘rings’(6%). After BLE treatment, as has
been described previously, RAD51 formed clear sub-
nuclear foci, and the numbers of cells which showed
such foci increased between 5 and 24 h (40 and 62% of
cells, respectively). The relative localization of
BRCA2myc and RAD51 in these conditions can be
broadly classiﬁed into two distinct types. First,
BRCA2myc localization in rings, where the signal was
generally continuous around the edge of the
DAPI-stained DNA, increased to 20% of cells after
BLE treatment (either 5 or 24 h). In most of these cells
(59%), no RAD51 foci were observed, but when RAD51
foci were seen, the signal was found within the
BRCA2myc ring (image 3, Figure 5), and thus the two
signals did not overlap. Second, although BLE treatment
caused no clear change in the number of cells with
punctate BRCA2myc localization, whether spread
throughout the nucleus or peripheral, more of these cells
displayed RAD51 foci. Despite this, co-localizaton of the
two proteins was remarkably rare. In 50% of the cells,
there was no overlap between the BRCA2myc and
RAD51 signals (image 4, Figure 5). Moreover, in the re-
maining 50% of cells where BRCA2myc and RAD51 co-
localization was observed, in no cases was there complete
co-localization of all ‘foci’ and, instead, it seemed that co-
localization was essentially always between a single
BRCA2myc ‘focus’ (that often made up part of a
punctate ring) and a single RAD51 focus, frequently out
of many (images 5 and 6, Figure 5). These data reveal
that T. brucei BRCA2 displays DNA damage-independent
localization to discrete subnuclear domains, including
focal-like structures, which is not observed for RAD51.
In addition, and in contrast to other eukaryotes,
DNA damage in T. brucei does not result in extensive
co-localization of the two repair factors in putative
repair foci; instead, although RAD51 forms such foci
in these conditions and they can be abundant in the
nucleus, co-localization of BRCA2 and RAD51 is
mainly limited to a single detectable focus. The same,
limited co-localization is seen in T. brucei BSF cells
(data not shown).
Trypanosoma brucei BRCA2 mutants have cell division
defects, not found in other DNA repair mutants, that
require the C-terminus of the protein
To ask whether we could identify a basis for the
pronounced growth impairment of the BSF T. brucei
brca2/ mutants, the cell cycle stage of individual BSF
cells was characterized by DAPI staining for DNA
content (45), which revealed that the brca2/– population
displayed abnormalities compared with WT, +/ and
//+ cells (Figure 6A). The / mutants showed an
12% reduction in the proportion of cells that contain
one nucleus and one kinetoplast (1N1K), which are in
the G1 or S phases of the cell cycle (45). This was not
associated with a concomitant accumulation of 1N2K or
2N2K cells, showing that the mutants do not arrest in
either the G2 or M phases, respectively. Instead, an
increase in aberrant cell types (‘others’) was found.
Detailed examination showed that this population con-
sisted of roughly equal number of cells with raised
kDNA and nDNA content (Figure 6B); raised kDNA
content was primarily in the form of cells with 0N1K,
0N2K or 1N3K DNA conﬁgurations, whereas those
with raised nDNA content were primarily 1N0K, 2N1K
or 2N0K cells (data not shown). A number of ﬁndings
argue that this phenotype is not a straightforward result
of the DNA repair deﬁciency of the brca2/ cells. First,
the same phenotype is not found in T. brucei mutants of
other DNA repair/recombination factors that result in
growth impairment: comparable analysis of rad51/
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mutants is shown in Figure 6A, and previous work has
examined mutants of MRE11 (46) and the RAD51
paralogues, RAD51-3 or RAD51-5 (8). Second, although
it is possible that BRCA2 has a more important role in
DNA damage repair than these other factors, meaning
that only brca2/ cells manifest a severe enough pheno-
type to visualize, this is not reﬂected in obviously greater
sensitivity to induced DNA damage compared with other
key repair/recombination factors (data not shown). Third,
if the phenotype was a consequence of unrepaired DNA
damage because of a DNA repair deﬁciency, then it might
be expected that induction of such damage would amplify
this phenotype. In fact, the cell cycle pattern observed
after BLE treatment of brca2/ cells was distinct: an
accumulation of 1N2K cells, not seen in undamaged
cells, was observed (data not shown); in addition, the
Figure 5. Immunolocalization of BRCA2 and RAD51 in T. brucei. Representative images are shown of BRCA2 and RAD51 localization in
individual PCF TREU927 T. brucei grown in the absence of phleomycin (no BLE) or after exposure to phleomycin (2 mgml1) for 5 h (BLE).
BRCA2 is an endogenously expressed Myc-tagged variant (BRCA2myc) and was detected with anti-Myc Alexa Fluor 488-conjugated antiserum
(1:7000 dilution). RAD51 was detected with polyclonal anti-RAD51 antiserum (1:1000 dilution) and secondary hybridization with Alexa Fluor 594
conjugated anti-rabbit antiserum (1:7000 dilution). Each cell is shown after staining with DAPI and as a merge of the BRCA2myc and RAD51
images (Merge). White arrows indicate co-localization between BRCA2myc and RAD51 signals.
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DNA content of the ‘other’ cells in these conditions dis-
played a pronounced accumulation of cells with raised
kDNA (or lowered nDNA) content (Figure 6B), primarily
because of the generation of 0N1K and 1N3K cells (data
not shown).
Examining 2N2K cells, which are undergoing mitosis
and are about to enter cytokinesis, suggested an explan-
ation for the generation of aberrant cells after BRCA2
loss. In WT, BRCA2+/ and BRCA2//+ parasites,
the majority of 2N2K cells had clearly separated nuclei,
with only 10–15% still visibly connected (Figure 6C and
D). In contrast, in a larger proportion (30–40%) of
brca2/ 2N2K cells, the two nuclei were visibly con-
nected, and, therefore, were still being segregated. Again,
this aberrant phenotype was not seen in rad51/
mutants (Figure 6D) or in rad51-3/ or rad51-5/
mutants (data not shown), suggesting it is not merely a
result of impaired growth. As the numbers of 2N2K cells
in the brca2/ mutants were not greater than in WT,
BRCA2+/ or BRCA2//+ cells (Figure 6A), this
indicates that in the absence of BRCA2 cytokinesis
proceeds while nuclear segregation is still occurring, re-
sulting in daughter cells that inherit both nuclei or none.
To dissect the role that BRCA2 plays in this function,
we expressed a number of BRCA2 variants in BSF cells,
again by integration into the tubulin array in brca2/
mutants (Figure 7A), which have been described before
(27). In brief, full-length BRCA2 from both T. brucei
and T. vivax was examined. The latter protein possesses
a single BRC repeat, and the two proteins share 26%
sequence identity over their whole length, increasing to
42% C-terminal of the BRC repeats. We also examined
the 1BRC variant, which retains only the C-terminal
repeat (Figure 4). Next, two truncated versions of
T. brucei BRCA2 were examined: one encompassed only
the BRC repeat region plus the C-terminal predicted
nuclear localization signal (NLS); the other encompassed
all sequence C-terminal to the BRC repeats, including the
same NLS. Finally, we examined a BRCA2 variant in
which the T. brucei BRC repeat region plus NLS was
Figure 6. A DNA replication or segregation defect in T. brucei bloodstream form BRCA2 mutants. (A) Nucleus (N) and kinetoplast (K) conﬁg-
urations of individual cells in a population were analysed by DAPI staining and microscopic examination. The percentage of cells with standard
(2N2K, 1N2K and 1N1K) or aberrant (other) N–K conﬁgurations is shown in WT Lister427 BSF T. brucei, in BRCA2+/ or brca2/ mutants, in
brca2/ cells in which full-length BRCA2 was re-expressed (//+), and in rad51/ mutants; the number of cells counted (N) is shown above the
graph. (B). Analysis of aberrant N–K conﬁgurations in two independent brca2/ mutants (1 or 2), detailing whether kDNA or nDNA content was
raised, before and after growth for 18 h in phleomycin (BLE). (C) Examples of 2N2K brca2/ cells undergoing nuclear segregation. (D). Analysis
of 2N2K cells from the populations described in A, detailing whether the nuclei were in the process of (incomplete) or had completed (complete),
segregation; N is indicated.
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translationally fused to the T. brucei RPA 50 kDa subunit,
which is homologous to the 70 kDa RPA-1 protein in
other eukaryotes. Previously, we have shown that this
fusion, which is structurally equivalent to similar fusions
examined in U. maydis (47) and mammalian cells (23), is
functional in supporting the relocalization of RAD51 to
subnuclear foci and in VSG switching, although it is
inefﬁcient in HR (27). Integration of each variant was
conﬁrmed by Southern analysis, and the expression of
each mRNA was shown to be equivalent by northern
blotting (27).
To examine the ability of the BRCA2 variants to
function in DNA repair, the sensitivity of each cell type
to MMS and BLE was compared (Figure 7B). As
described earlier in the text, ectopic expression of full-
length T. brucei BRCA2 by this approach not only com-
plemented the sensitivity of brca2/ cells to each agent
but also (in particular for MMS) resulted in greater resist-
ance than WT cells. The BRC–RPA fusion protein func-
tioned as efﬁciently as full-length BRCA2 in response to
MMS, and it provided partial complementation of BLE
sensitivity, indicating that repair can be catalysed in the
absence of BRCA2 C-terminal sequence. This is consistent
with the ability of this fusion to support RAD51 foci for-
mation after BLE treatment in T. brucei (27) and, more
broadly, with the functioning of a BRC–RPA fusion in
response to ultraviolet irradiation in U. maydis (47) and in
response to mitomycin C or ionising radiation damage in
mammals (23). Neither of the BRCA2 variants with only
one BRC repeat supported fully efﬁcient repair.
Expressing the T. brucei 1BRC variant, as described
earlier in the text, partly alleviated the brca2/
mutant’s sensitivity to BLE and MMS but to a lesser
extant that the BRC–RPA fusion. Cells expressing
Figure 7. Assessing T. brucei BRCA2 variant function in DNA repair and replication. (A) Diagrammatic representation of BRCA2 variants
expressed in Lister427 BSF brca2/ mutants, using the same strategy as described in Figure 3. The full-length T. brucei BRCA2 used here
(TbBRCA2) contains 12 BRC repeats, a conserved DBD and two putative NLS. BRCA2 from T. vivax (TvBRCA2) has a single BRC repeat
and a conserved DBD, but no NLSs have been predicted. 1BRC is identical to full-length T. brucei BRCA2, but the BRC array is reduced to a single
repeat (Figure 3). BRCrep is a polypetide fragment of T. brucei BRCA2 encompassing only the BRC repeats and 33 downstream amino acids,
including a bipartite NLS. Cterm is a 747 amino acid residue N-terminal truncation of T. brucei BRCA2. BRC–RPA is a fusion of the BRCrep
polypeptide to the 50 kDa T. brucei replication protein A subunit. (B) The concentration of MMS or phleomycin (BLE) that caused 50% growth
inhibition (EC50) of WT cells is compared with brca2/ mutants, and with / cells expressing the BRCA2 variant polypeptides detailed in A.
Values are the means from three experiments; bars indicate standard error. (C) The relative proportions of cells with standard (2N2K, 1N2K and
1N1K) or aberrant (other) nuclear (N) and kinetoplast (K) conﬁgurations are compared in populations of WT cells, brca2/ mutants and / cells
expressing the BRCA2 variant polypeptides detailed in A. N–K conﬁgurations were analysed by DAPI staining and microscopic examination; the
number of cells counted (N) is indicated.
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T. vivax BRCA2 were profoundly sensitive to both DNA
damaging agents, to an extent comparable with the BRC
repeat polypeptide and the polypeptide C-terminal to the
repeats.
To test the ability of the BRCA2 variants to provide for
efﬁcient cell division, we analysed the cells’ DNA content
by DAPI staining, asking whether the different cells dis-
played the abnormalities noted in the brca2/ mutants
(Figure 7C). The BRC–RPA expresser cells, which were
signiﬁcantly more proﬁcient in DNA repair than the
brca2/ cells, continued to display an increased
number of aberrant cells, indicating that the brca2/
replication defect is not complemented by this protein.
In contrast, the cells expressing either of the BRCA2
variants with 1BRC repeat, which were deﬁcient in
DNA repair, no longer displayed an increase in ‘others’.
Remarkably, the cells that expressed the C-terminus of
BRCA2, missing all BRC repeats, showed partial comple-
mentation, as the number of ‘others’ was signiﬁcantly
fewer than seen in the brca2/ mutants and in the
BRC–RPA-expressing or BRC repeat polypeptide-
expressing cells. Taken together, these ﬁndings demon-
strate that the replication or cell division deﬁciency seen
in brca2/ mutants is a consequence of a function that
can be separated from the BRC repeats and resides, at
least partially, in the C-terminal portion of T. brucei
BRCA2.
Reducing RAD51 expression levels in T. brucei leads to
DNA repair and recombination defects
In the above analysis, although we detect visible
relocalization of T. brucei RAD51 to subnuclear foci
after BLE-induced damage, an increase in the expression
of the recombinase is not seen (Supplementary Figures S7
and S9). Moreover, induction of a T. brucei locus-speciﬁc
DNA DSB also does not result in RAD51 upregulation
(48). Such lack of RAD51 expression upregulation is
surprising, as this conserved response to DNA damage
is seen in closely related kinetoplastid parasites: increased
levels of RAD51 mRNA and protein are seen after BLE
treatment of Leishmania (35,49) and ionising radiation of
T. cruzi (50) (our unpublished data). Given this, we
decided to ask whether the abundance of RAD51 is im-
portant in T. brucei. To do this, we re-expressed RAD51
in BSF Lister427 rad51/ mutants using the tubulin in-
tegration strategy adopted for BRCA2 (Figure 8A). To
ensure reproducibility, two independent rad51/
mutant clones (Figure 8C) were generated, in each case
by two rounds of transformation that were performed in
parallel from the same WT cells, each leading to ORF
disruption (data not shown); in each mutant, the
RAD51 ORF was then re-introduced (//+RAD51).
Western blots showed that this expression strategy
resulted in reduced levels of RAD51 protein relative to
WT cells and that, like in WT, these levels were not
altered by BLE treatment (Figure 8B). BSF rad51/
cells are impaired in in vitro growth and re-expression of
RAD51, even at these reduced levels, complemented this
deﬁciency (data not shown). However, each of the RAD51
re-expresser cells were deﬁcient in repair of BLE-induced
damage, displaying EC50 values that were close to those of
the rad51/ mutants and 2–3-fold lower than WT
(Figure 8C). Using a transformation assay described pre-
viously (27), it was revealed that limiting the amount of
RAD51 also affected the efﬁciency of HR: the
re-expressers were only capable of integrating DNA at
60% of the frequency of WT, indicating impairment,
although not as severe as in rad51/ cells (Figure 8D).
These data indicate that the levels of RAD51 expressed
from the tubulin array are insufﬁcient to support DNA
repair and HR at efﬁciencies seen in WT cells, indicating
that, unlike BRCA2, RAD51 abundance seems limiting
for these processes.
DISCUSSION
The initial impetus for this study was to understand why
BRCA2 in T. brucei, a diverged eukaryote that exploits
HR for antigenic variation, has evolved a striking expan-
sion in the number of BRC repeat motifs that mediate
interaction with RAD51, the key eukaryotic HR catalytic
factor. In examining this, we have revealed a number of
further aspects of BRCA2 function. We propose that these
ﬁndings can be explained by a model (Figure 9) in which
the BRC repeat expansion has evolved to allow BRCA2 to
operate in dual functions in T. brucei: a putative
repair-independent role in the maintenance of the VSG
repository, and HR repair of generalized genome
damage. Later in the text we outline these ﬁndings and
discuss this proposal.
BRC repeats are a critical motif of BRCA2, conserved
in all homologues (11), but their detailed function is still
unclear. One important question in considering this
function is why some organisms, such as mammals,
plants and T. brucei, encode BRCA2 homologues with
multiple BRC repeats, whereas others, such as
C. elegans and U. maydis, function with single-BRC
repeat homologues. Taking advantage of the unusual ar-
rangement of the T. brucei BRC repeats as an array, we
have been able to generate T. brucei cells expressing
BRCA2 variants in which the BRC repeat copy number
is systematically reduced. This revealed that BRC repeat
number in T. brucei is a critical determinant of the efﬁ-
ciency with which RAD51 localizes to visible subnuclear
foci after induced DNA damage. This is not because
BRCA2 acts to transit RAD51 to the T. brucei cell
nucleus, which seems to be a functional divergence from
human and Leishmania BRCA2 (34,35). Instead, T. brucei
BRCA2’s role via the BRC repeats is in the subnuclear
redistribution of RAD51. Despite this, reducing the BRC
repeat number has a remarkably limited effect on the ef-
ﬁciency of DNA damage repair. BRCA2 with a single-
BRC repeat is repair-deﬁcient in BSF T. brucei cells,
whereas variants with four or more repeats function as
efﬁciently as BRCA2 with a full complement of 12 BRC
repeats. In PCF cells, even one BRC repeat can support
fully efﬁcient DNA damage repair. This provides a more
complete picture of the functional signiﬁcance of the
BRCA2 BRC repeat expansion that we reported
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Figure 8. Expression of RAD51 from tubulin in T. brucei lowers the cellular levels of the protein and leads to repair and recombination deﬁciency.
(A) RAD51 was re-expressed in Lister427 BSF rad51/ cells using the same strategy for ORF integration into tubulin used for BRCA2 (see
Figure 3). (B) Western blots are shown of whole cell extracts from WT cells and from a RAD51 re-expresser (//+) cells, each grown in the absence
or presence of phleomycin (BLE; 1mg ml1 for 18 h). RAD51 was detected using polyclonal anti-RAD51 antiserum, and the blot was then stripped
and re-probed with anti-OPB antiserum to compare loading. (C) The concentration of BLE that caused 50% growth inhibition (EC50) of WT cells is
compared with two independently generated rad51/ mutants (B and C), and with each / cell re-expressing RAD51 from tubulin (//+);
values are the means from three experiments and bars indicate standard error. (D) To assay recombination, the number of antibiotic resistant clones
recovered when the construct tub-HYG-tub (27) was transformed into WT cells, rad51/ mutants and RAD51 re-expresser (//+) cells was
determined; values shown are the means from three experiments (expressed as number of transformants per 106 cells put on selection), and bars
indicate standard error.
Figure 9. A model for the dual function of BRCA2 in T. brucei genome stability. The genome of T. brucei is represented by a single chromosome
(black line inside the nucleus, which is shown as black circle) in which silent VSGs (light grey arrows) in the subtelomere are shown, as well as two
genes (A and B; dark grey arrows) that represent the heavily transcribed chromosome core (transcription represented by a long arrow). BRCA2 (red
circle) is shown to predominantly localize to the VSGs in undamaged cells, where is acts to ensure stable transmission of these genes and recruits
RAD51 (blue circle). After DNA damage in the core (gene B in this example) repair is mediated by BRCA2 acting to relocalize RAD51 to the site of
damage, where RAD51 becomes concentrated in microscopically detectable subnuclear foci.
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previously (27), and indicates that this adaptation is not
because of T. brucei-speciﬁc aspects of general HR repair.
Gross chromosomal rearrangements (GCRs) are a
hallmark phenotype of BRCA2 mutation or loss: these
are manifest as chromosome loss, breakage and transloca-
tion (51) in mammals, and similar genome instability is
seen in U. maydis (12) and during meiosis in A. thaliana
(52) and C. elegans (53). In T. brucei, loss of BRCA2 also
leads to genome instability (27). However, we now show
that this is limited to mammal-derived BSF cells, with
PCF cells derived from the tsetse ﬂy midgut showing no
evidence for substantial chromosome alterations. Such a
life cycle stage- or cell type-speciﬁc role for BRCA2 in
genome stability is unprecedented to our knowledge. It
seems likely that this is because the BSF instability is
not because of genome-wide GCRs, but is limited to the
VSG repository. Intermediate and mini-chromosomes,
which do not harbour silent VSG arrays, show no instabil-
ity in brca2/ BSF cells (27). Furthermore, in an
attempt to track rearrangements in the megabase-chromo-
somes, we probed Southern blots of BSF brca2/
mutant clones for ingi retrotransposons, which are found
in non-coding regions throughout the T. brucei genome,
including within the subtelomeric VSGs arrays (54). No
evidence for rearrangements was seen (Supplementary
Figure S13), indicating that genome instability may
largely be limited to loss of VSGs, which is consistent
with the predominant reduction in chromosome size in
the mutants (27) and may reﬂect the plasticity of the
VSG repertoire between and within T. brucei strains (41).
Examination of the DNA content of individual BSF
brca2/ cells indicates that T. brucei BRCA2 provides
genome maintenance functions that can be separated from
DNA repair. Unique among mutants of T. brucei DNA
repair factors examined to date, brca2/ mutants
display an accumulation of cells with abnormal ratios of
nuclear (N) and kinetoplast (K) DNA. These do not arise
because of changes in the number of cells with 1N2K and
2N2K composition, indicating that this phenotype is a
consequence of impairment in nuclear DNA replication
or segregation (separation of the nucleus or nuclear
genome during mitosis), and does not affect the kineto-
plast. A number of lines of evidence indicate that DNA
replication/segregation and DNA damage repair are
separate functions of BRCA2. First, BRCA2 variants
with only one BRC repeat are impaired in repair of
DNA damage in BSF cells, but function normally in
DNA replication/segregation. Second, a fusion of BRC–
RPA, as has been seen in other organisms (23,47), is
capable of functioning in T. brucei DNA repair and in
localizing RAD51 to subnuclear foci (27), but cannot
complement the replication/segregation defect of
brca2/ cells. This suggests that the C-terminus of
BRCA2 (downstream of the BRC repeats) is needed for
this role, and, indeed, we ﬁnd that this C-terminal region,
when expressed in isolation, is able to partially comple-
ment the replication/segregation deﬁciency. These data
seem consistent with ﬁndings from vertebrate BRCA2
studies. Schlacher et al. (25) have shown that the
C-terminus of mammalian BRCA2 acts to stabilize
Rad51 ﬁlaments that form at stalled replication forks,
protecting them from MRE11 degradation; indeed, a
BRC–RPA fusion was impaired in this process, consistent
with the lack of functionality we observed for an equiva-
lent T. brucei fusion in replication/segregation. It is likely
that such a role is related to the demonstration that
Xenopus Rad51 binds ssDNA gaps that can form behind
replication forks, again protecting them from MRE11
degradation (26). Our work may then reveal that this
BRCA2 function is widely conserved in eukaryotes, with
some caveats. We do not yet know whether T. brucei
BRCA2’s replication/segregation function underlies the
genome instability we observe; therefore, it is unclear
whether this is BSF-speciﬁc or is a general role whose
importance becomes more pronounced in this life cycle
stage. In addition, we do not yet know whether T. brucei
RAD51 acts in this function (see later in the text), al-
though it is notable that although the C-terminus of
T. brucei BRCA2 is highly diverged from vertebrates, it
does interact with the recombinase (our unpublished data)
and that it has been suggested to bind CDC45 (55),
perhaps providing a direct link with the replication ma-
chinery. Finally, we cannot exclude the possibility that
T. brucei BRCA2’s role is due to a function in mitosis
or cytokinesis, activities that some work in vertebrate
cells has linked BRCA2 with (24,56–59), although we
ﬁnd no evidence for speciﬁc localization of BRCA2 in
mitotic (2N2K) cells (data not shown).
The function of BRCA2 in DNA damage repair has
been closely linked with Rad51 through cytological
studies of repair foci induced by exogenous DNA
damage. In the absence of induced damage, mammalian
BRCA2 is nuclear but shows little subnuclear localization
(60), whereas after damage, BRCA2 relocalizes to discrete
foci that co-localize extensively with Rad51 foci (61). The
same behaviour is seen for Drosophila BRCA2 and Rad51
(44). Although co-localization of Rad51 and Brh2/
BRCA2 has not been described in U. maydis, each
factor localizes to detectable subnuclear foci at similar
times after DNA damage (62). The subnuclear dynamics
of T. brucei BRCA2 and RAD51 differ from these ﬁndings
in several important ways. First, T. brucei BRCA2 in the
absence of induced damage displays substantial nuclear
localization, predominantly in punctate, focal-like struc-
tures around the nuclear periphery or throughout the
nucleus, as well as in peripheral ‘rings’. This extensive
nuclear localization contrasts with RAD51, which is de-
tectable in subnuclear foci rarely (2% of cells) in these
conditions. This dichotomy is not because of detection of
BRCA2 via a Myc epitope, as RAD51 tagged in the same
way displays the same behaviour as endogenous RAD51
detected by polyclonal antiserum (our unpublished data).
Although it is formally possible that the tagging strategy
altered BRCA2 protein levels, for instance, by changing
mRNA abundance because of altering the 30-UTR, we
have not seen any indication of this. Second, T. brucei
BRCA2 and RAD51 rarely co-localize in multiple foci
after BLE-induced damage. Although both proteins can
be seen in multiple foci in a single cell, we rarely detect co-
localization beyond a single focus. These ﬁndings are com-
patible with BRCA2 in the parasite acting both in DNA
repair and in an additional role. Co-localization could
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represent T. brucei BRCA2 establishing RAD51 repair
foci and then moving away, leaving the recombinase foci
in place. The subnuclear localization of T. brucei BRCA2
that is distinct from RAD51 may be because of a
pronounced genome maintenance role; RAD51 may be
recruited to this function without forming cytologically
detectable foci or it may not act.
Taken together, we suggest that above data are consist-
ent with a model (Figure 9) in which T. brucei BRCA2,
like that of mammals, acts through the C-terminus to
ensure correct transmission of nuclear DNA. In
T. brucei, this has additional importance in maintenance
and transmission of the VSG-containing subtelomeres,
which can be peripheral in the nucleus (63) and would
explain the persistent localization we see of BRCA2.
Moreover, this role has selected for an expanded array
of BRC repeats, which are needed to allow BRCA2 to
be re-directed from this function to act in general repair
when needed. This would match the BRCA2 variant data
that we describe. The T. brucei BRCA2 variant in which
the normal C-terminus has been replaced, like the same
fusion in mammals, is free to mediate repair via the BRC
repeats but does not act in replication/segregation (25).
Furthermore, in T. brucei, a BRCA2 variant with a
single BRC repeat linked to the normal C-terminus is
repair-deﬁcient in BSF cells because it acts preferentially
in replication/segregation, to the detriment of repair. We
suggest that T. brucei BRCA2’s C-terminus, like that of
mammalian BRCA2, acts in this role through targeting
RAD51. The importance of this role has selected for
T. brucei RAD51 expression becoming non-responsive to
damage (and thus distinct from T. cruzi and Leishmania)
(49,50), leading to an abundant pool of the recombinase.
This would explain why BRCA2 variants with increasing
BRC repeat number display greater numbers of RAD51
foci: when DNA damage is present in excess (e.g. through
treatment with BLE), these variants are increasingly
capable of relocating the abundant RAD51 from the rep-
lication/segregation role to sites of damage. In addition, if
RAD51 is preferentially targeted to the transmission role,
then reducing the expression level of RAD51 would lead
to the observed repair deﬁciency. The problems associated
with maintenance or transmission of the subtelomeric
VSG arrays are, as yet, unknown. One possibility is that
there is frequent and unseen recombination among the
VSGs, leading to gaps that must be protected to avoid
them leading to gene loss, as seen in brca2/ mutants.
Whether this is associated with replication is unknown,
although we see no evidence that the BRCA2 localization
alters in S-phase cells (data not shown). This process may
be common to both PCF and BSF cells, as the punctate
BRCA2 localization is seen in the former. However, we
suggest that the frequency of the putative gaps increases in
BSF cells, either because the VSG arrays undergo a
change to make them more ‘fragile’ or because the VSG
expression sites begin to ‘sample’ the VSG arrays during
antigenic variation, placing a further burden on BRCA2
and RAD51. This would explain why VSG instability in
brca2/ mutants is seen speciﬁcally in BSF cells, why
PCF brca2/ mutants have less severe repair defects
and why BRC variants with lowered BRC repeat
number are more capable of redirecting RAD51 to
induced damage in PCF cells than in BSF cells.
The model for BRCA2 function we propose is sup-
ported by a recent comparison of VSG composition in
T. brucei, T. congolense and T. vivax (64). Each of these
Trypanosoma species contains a repository of VSGs that
allows immune evasion by antigenic variation, but we
have previously reported that this is not reﬂected in a
common BRCA2 architecture: T. congolense BRCA2
possesses three highly sequence-related arrayed BRC
repeats, whereas T. vivax BRCA2 has a single BRC
repeat (27). These differences in BRCA2 organization
can now be explained, as differences in VSG recombin-
ation frequency and mechanism are found between the
species (64). In T. brucei and T. congelense, recombination
between VSGs is more frequent than in T. vivax.
Furthermore, in T. brucei recombination seems to be
able to occur relatively freely throughout the VSG reposi-
tory, leading to a greater number of VSG pseudogenes,
whereas in T. congolense, the VSGs fall into more clearly
deﬁned clades, with fewer pseudogenes, indicative of re-
combination that is more restricted. Our work shows that
this ongoing VSG diversiﬁcation, which is accelerated in
T. brucei, has had an impact on the structure of a core
element of the HR machinery, emphasizing how antigenic
variation and HR intersect.
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